tafenoquine has been researched along with Malaria in 50 studies
*Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.00) | 18.7374 |
| 1990's | 6 (12.00) | 18.2507 |
| 2000's | 10 (20.00) | 29.6817 |
| 2010's | 25 (50.00) | 24.3611 |
| 2020's | 7 (14.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blumbergs, P; LaMontagne, MP; Smith, DC | 1 |
| Ager, A; Ellis, W; Guan, J; Kyle, D; Lin, AJ; Milhous, W; Sacci, J; Zhang, Q | 1 |
| Charles, BG; Edstein, MD; Harris, IE; Miller, AK; Nasveld, PE; Reid, MG | 1 |
| Ager, AL; Bartlett, MS; Croft, SL; Khan, IA; McChesney, JD; Nanayakkara, NP; Walker, LA; Yardley, V | 1 |
| Brennan, L; Edstein, MD; Harris, IE; Kerr, C; Kitchener, SJ; Leggat, PA; Nasveld, PE; Ohrt, C; Pickford, P; Prescott, W; Reid, M | 1 |
| Hudson, TH; Kozar, MP; Lin, AJ; Magill, AJ; Melendez, V; Ohrt, C; Shiraki, H | 1 |
| Kozar, MP; Li, Q; Lin, AJ; Liu, X; Melendez, V; O'Neil, MT; Wang, X | 1 |
| Caridha, D; Kozar, MP; Lin, AJ; O'Neil, MT; Pybus, B; Sathunuru, R; Zhang, L | 1 |
| Avery, VM; Baragaña, B; Campbell, SF; Delves, MJ; Duffy, S; Fairlamb, AH; Frearson, JA; Gilbert, IH; Gray, DW; Grimaldi, R; Hallyburton, I; Meister, S; Norcross, NR; Norval, S; Osuna-Cabello, M; Porzelle, A; Read, KD; Riley, J; Simeons, FR; Sinden, RE; Stojanovski, L; Waterson, D; Willis, P; Wilson, C; Winzeler, EA; Wittlin, S; Wyatt, PG | 1 |
| Attaher, O; Bousema, T; Bradley, J; Diallo, M; Dicko, A; Dicko, OM; Drakeley, C; Issiaka, D; Keita, S; Lanke, K; Maguiraga, SO; Mahamar, A; McCall, MBB; Niambele, SM; Sacko, A; Samake, S; Sanogo, K; Sinaba, Y; Smit, MJ; Stone, W; Ter Heine, R; Traore, SF | 1 |
| Baird, JK; Berni, A; Budiman, W; Cedar, E; Chand, K; Crenna-Darusallam, C; Duparc, S; Ekawati, LL; Elyazar, I; Fernando, D; Fletcher, K; Goyal, N; Green, JA; Instiaty, I; Jones, S; Kleim, JP; Lardo, S; Martin, A; Noviyanti, R; Prasetya, CB; Rolfe, K; Santy, YW; Satyagraha, AW; Sharma, H; Soebandrio, A; Subekti, D; Sutanto, I; Tan, LK; Taylor, M | 1 |
| Bassat, Q; Brito-Sousa, JD; Costa, FT; King, L; Lacerda, MV; Luzzatto, L; Monteiro, WM; Siqueira, AM; Val, F | 1 |
| Haston, JC; Hwang, J; Tan, KR | 1 |
| Commons, RJ; McCarthy, JS; Price, RN | 1 |
| Carr, KA; Clarke, JG; Kreishman-Deitrick, M; Shmuklarsky, MJ; Zottig, VE | 1 |
| Calvaresi, EC; Genzen, JR | 1 |
| Clark, J; Clements, ACA; Doi, SAR; Furuya-Kanamori, L; Islam, N; Lau, CL; Mills, DJ; Wright, S | 1 |
| Baird, JK | 2 |
| Ashley, EA; Phyo, AP | 1 |
| Frampton, JE | 1 |
| Fukuda, MM; Martin, N; Waters, NC; Wojnarski, M; Zottig, V | 1 |
| Freedman, DO | 1 |
| Meltzer, E; Schwartz, E | 1 |
| Kain, KC | 1 |
| Chu, CS; Freedman, DO | 1 |
| Mordue, DG; Wormser, GP | 1 |
| Fernando, SD; Rajapakse, S; Rodrigo, C | 1 |
| Shanks, GD | 1 |
| Bennett, JW; Careagabarja, J; Caridha, D; Deye, G; Dhammika Nanayakkara, NP; Hickman, M; Li, Q; Marcsisin, SR; McNulty, R; Melendez, V; Pybus, BS; Read, L; Reichard, GA; Roncal, N; Sciotti, RJ; Smith, B; Sousa, JC; Walker, LA; Zeng, Q; Zottig, VE | 1 |
| Caridha, D; Hickman, M; Li, Q; Melendez, V; O'Neil, M; Pybus, B; Xie, L; Zeng, Q; Zhang, J | 1 |
| Berman, J; DiTusa, C; Gettayacamin, M; Im-erbsin, R; Kozar, MP; Ohrt, C; Pybus, B; Sousa, J; Tungtaeng, A | 1 |
| deKock, C; Dube, A; Gibhard, L; Hayeshi, R; Kalombo, L; Melariri, P; Nkuna, P; Ogutu, B; Smith, P; Swai, H; Wiesner, L | 1 |
| Berman, J; Caridha, D; Dickson, SP; Hickman, M; Lee, PJ; Li, Q; Marcsisin, SR; Milner, EE; Read, LT; Roncal, N; Vesely, BA; Xie, LH; Zhang, J; Zhang, P | 1 |
| Cozens, S; Dow, GS; Gettayacamin, M; Hansukjariya, P; Imerbsin, R; Kenworthy, D; Komcharoen, S; Kyle, D; Milhous, W; Miller, A; Ohrt, C; Sattabongkot, J; Veazey, J | 1 |
| Dutta, GP; Puri, SK | 1 |
| Peters, W; Robinson, BL; Stewart, LB | 1 |
| Jomaa, H; Ortmann, R; Schlitzer, M; Wiesner, J | 1 |
| Chambers, JA | 1 |
| Milhous, WK; Peters, W; Robinson, BL | 1 |
| Fleck, SL; Peters, W; Robinson, BL | 1 |
| Peters, W | 1 |
| Kremsner, P | 1 |
| Kain, KC; Keystone, JS; Shanks, GD | 1 |
| Eamsila, C; Edstein, MD; Kitchener, S; Nasveld, PE; Rieckmann, KH; Sasiprapha, T; Walsh, DS | 1 |
| Trigg, PI | 1 |
| Coleman, RE | 1 |
| Gutteridge, WE | 1 |
13 review(s) available for tafenoquine and Malaria
| Article | Year |
|---|---|
Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019.
Topics: Aminoquinolines; Antimalarials; Centers for Disease Control and Prevention, U.S.; Humans; Malaria; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Secondary Prevention; Travel Medicine; United States | 2019 |
Efficacy of a 3-day pretravel schedule of tafenoquine for malaria chemoprophylaxis: a network meta-analysis.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria; Mefloquine; Network Meta-Analysis; Travel | 2021 |
Drugs in Development for Malaria.
Topics: Aminoquinolines; Antimalarials; Artemisinins; Drug Discovery; Drug Resistance, Multiple; Ferrous Compounds; Humans; Imidazoles; Lumefantrine; Malaria; Metallocenes; Piperazines; Signal Transduction; Treatment Outcome | 2018 |
Tafenoquine: First Global Approval.
Topics: Aminoquinolines; Antimalarials; Drug Approval; Humans; Malaria; Treatment Outcome; United States; United States Food and Drug Administration | 2018 |
Tafenoquine and G6PD: a primer for clinicians.
Topics: Aminoquinolines; Antimalarials; Contraindications, Drug; Dose-Response Relationship, Drug; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria; Randomized Controlled Trials as Topic; Recurrence | 2019 |
Tafenoquine for primary and terminal prophylaxis of malaria in apparently healthy people: a systematic review.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria; Treatment Outcome | 2019 |
Expanded table: drugs for prophylaxis of malaria.
Topics: Aminoquinolines; Antimalarials; Atovaquone; Drug Combinations; Humans; Malaria; Pre-Exposure Prophylaxis; Statistics as Topic; Travel | 2019 |
New antimalarial drugs.
Topics: Aminoquinolines; Animals; Antimalarials; Artemisinins; Artesunate; Atovaquone; Clinical Trials as Topic; Dapsone; Drug Combinations; Drug Design; Drug Resistance; Ethanolamines; Flavonoids; Fluorenes; Fosfomycin; Global Health; Humans; Lumefantrine; Malaria; Naphthoquinones; Naphthyridines; Plasmodium falciparum; Proguanil; Sesquiterpenes | 2003 |
Military aviators, special operations forces, and causal malaria prophylaxis.
Topics: Aminoquinolines; Antimalarials; Atovaquone; Aviation; Chloroquine; Doxycycline; Drug Combinations; Humans; Malaria; Mefloquine; Military Personnel; Naphthoquinones; Primaquine; Proguanil; United States | 2003 |
The evolution of tafenoquine--antimalarial for a new millennium?
Topics: Aminoquinolines; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Primaquine | 1999 |
Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future.
Topics: Aminoquinolines; Animals; Antimalarials; Drug Resistance; Humans; Malaria; Plasmodium; Primaquine; Travel | 2001 |
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Military Personnel; Primaquine | 2001 |
Antimalarial drugs currently in development.
Topics: Aminoquinolines; Antimalarials; Artemisinins; Atovaquone; Chemical Phenomena; Chemistry; Drug Design; Drug Evaluation, Preclinical; Drug Resistance; Humans; Malaria; Naphthoquinones; Research; Sesquiterpenes | 1989 |
5 trial(s) available for tafenoquine and Malaria
| Article | Year |
|---|---|
Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Double-Blind Method; Female; Humans; Malaria; Male; Middle Aged; Military Personnel; Models, Biological | 2007 |
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Topics: Adult; Aminoquinolines; Antimalarials; Australia; Double-Blind Method; Female; Humans; Malaria; Male; Mefloquine; Middle Aged; Military Personnel; Treatment Outcome; Young Adult | 2010 |
Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.
Topics: Aminoquinolines; Animals; Artemisinins; Humans; Malaria; Malaria, Falciparum; Mali; Piperazines; Plasmodium falciparum; Quinolines; Single-Blind Method | 2022 |
Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Therapy, Combination; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine; Quinolines | 2023 |
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Military Personnel; Primaquine | 2001 |
33 other study(ies) available for tafenoquine and Malaria
| Article | Year |
|---|---|
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
Topics: Aminoquinolines; Animals; Antimalarials; Chemical Phenomena; Chemistry; Malaria; Mice; Plasmodium berghei; Structure-Activity Relationship | 1989 |
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
Topics: Administration, Oral; Animals; Antimalarials; Carbamates; Guanidines; Imidazoles; Imidazolidines; Malaria; Male; Mice; Plasmodium falciparum; Plasmodium yoelii; Structure-Activity Relationship | 2005 |
Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.
Topics: Aminoquinolines; Animals; Antifungal Agents; Antiprotozoal Agents; Dogs; Female; Hemolysis; Humans; Leishmania donovani; Leishmaniasis, Visceral; Malaria; Male; Methemoglobinemia; Mice; Mice, Inbred BALB C; Plasmodium berghei; Pneumocystis carinii; Pneumonia, Pneumocystis; Stereoisomerism; Structure-Activity Relationship | 2008 |
Antimalarial activity of novel 5-aryl-8-aminoquinoline derivatives.
Topics: Aminoquinolines; Animals; Antimalarials; Cell Line; Chloroquine; Drug Resistance; Humans; In Vitro Techniques; Malaria; Mice; Microsomes, Liver; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship | 2011 |
Synthesis and antimalarial activity of 2-guanidino-4-oxoimidazoline derivatives.
Topics: Administration, Oral; Animals; Antimalarials; Guanidines; Imidazolidines; Imidazolines; Macaca mulatta; Malaria; Mice; Plasmodium berghei; Plasmodium cynomolgi; Plasmodium falciparum; Prodrugs; Structure-Activity Relationship | 2011 |
Antimalarial activities of new guanidylimidazole and guanidylimidazoline derivatives.
Topics: Animals; Antimalarials; Crystallography, X-Ray; Guanidines; Humans; Imidazoles; Imidazolines; In Vitro Techniques; Macaca mulatta; Malaria; Mice; Microsomes, Liver; Plasmodium berghei; Plasmodium falciparum; Recurrence; Structure-Activity Relationship | 2011 |
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
Topics: Animals; Antimalarials; Disease Models, Animal; Drug Discovery; Malaria; Mice; Molecular Structure; Plasmodium falciparum; Quinolines; Structure-Activity Relationship | 2016 |
Tafenoquine for the prophylaxis, treatment and elimination of malaria: eagerness must meet prudence.
Topics: Aminoquinolines; Animals; Antimalarials; Drug Evaluation; Humans; Malaria; Plasmodium vivax; Randomized Controlled Trials as Topic | 2019 |
Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency.
Topics: Aminoquinolines; Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; Male; Practice Guidelines as Topic; Primaquine | 2020 |
Army Antimalarial Drug Development: An Advanced Development Case Study for Tafenoquine.
Topics: Aminoquinolines; Antimalarials; Drug Development; Humans; Malaria; Military Personnel | 2020 |
Evaluating Percentage-Based Reporting of Glucose-6-Phosphate Dehydrogenase (G6PD) Enzymatic Activity.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Child; Child, Preschool; Female; Glucosephosphate Dehydrogenase; Hematologic Tests; Humans; Infant; Malaria; Male; Middle Aged; Reference Values; Retrospective Studies; Young Adult | 2020 |
Single loading-dose tafenoquine for malaria chemoprophylaxis during brief travel?
Topics: Aminoquinolines; Chemoprevention; Humans; Malaria | 2021 |
Tafenoquine for travelers' malaria: evidence, rationale and recommendations.
Topics: Adult; Aminoquinolines; Antimalarials; Dose-Response Relationship, Drug; Female; Humans; Infection Control; Malaria; Malaria, Vivax; Male; Travel; United States; United States Food and Drug Administration | 2018 |
Editorial: Malaria in the Korean peninsula: Risk factors, latent infections, and the possible role of tafenoquine, a new antimalarial weapon.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria; Military Personnel | 2018 |
Tafenoquine: integrating a new drug for malaria prophylaxis into travel medicine practice.
Topics: Aminoquinolines; Humans; Malaria; Travel; Travel Medicine | 2019 |
Atovaquone-proguanil chemoprophylaxis in the era of Tafenoquine.
Topics: Aminoquinolines; Antimalarials; Atovaquone; Chemoprevention; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Proguanil; Travel | 2019 |
Single-dose radical cure for Plasmodium vivax.
Topics: Aminoquinolines; Humans; Malaria; Plasmodium vivax; Primaquine; Travel | 2019 |
Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?
Topics: Aminoquinolines; Animals; Babesia microti; Babesiosis; Female; Malaria; Mice; Mice, SCID; Parasitemia; Plasmodium | 2019 |
Tafenoquine (Arakoda; Krintafel) for malaria.
Topics: Aminoquinolines; Antimalarials; Delayed-Action Preparations; Humans; Malaria; Randomized Controlled Trials as Topic; Travel | 2019 |
Possible options for malaria chemoprophylaxis on the horizon.
Topics: Aminoquinolines; Antimalarials; Azithromycin; Chemoprevention; Doxycycline; Drug Therapy, Combination; Humans; Malaria; Medication Adherence; Primaquine | 1999 |
Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.
Topics: Aminoquinolines; Animals; Antimalarials; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Malaria; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plasmodium berghei; Succinates | 2014 |
Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.
Topics: Aminoquinolines; Animals; Antimalarials; Area Under Curve; Flow Cytometry; Half-Life; Liver; Malaria; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Plasmodium berghei; Primaquine; Sporozoites | 2014 |
Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model.
Topics: Aminoquinolines; Animals; Antimalarials; Atovaquone; Disease Models, Animal; Drug Combinations; Macaca mulatta; Malaria; Parasitemia; Plasmodium cynomolgi; Primaquine; Proguanil | 2014 |
Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice.
Topics: Administration, Oral; Aminoquinolines; Animals; Antimalarials; Biological Availability; Erythrocytes; Humans; Malaria; Mice; Nanostructures; Plasmodium berghei; Plasmodium falciparum | 2015 |
Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.
Topics: Aminoquinolines; Animals; Antimalarials; Chemoprevention; Cytochrome P-450 CYP2D6; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy; Female; Malaria; Male; Mice, Inbred C57BL; Mice, Knockout; Plasmodium berghei; Primaquine; Treatment Outcome | 2016 |
Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta).
Topics: Aminoquinolines; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chloroquine; Chromatography, Liquid; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Macaca mulatta; Malaria; Male; Mass Spectrometry; Mefloquine; Plasma; Plasmodium cynomolgi; Primate Diseases; Quinine; Treatment Outcome | 2011 |
Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys.
Topics: Aminoquinolines; Animals; Antimalarials; Female; Macaca mulatta; Malaria; Male; Monkey Diseases; Parasitemia; Plasmodium cynomolgi; Primaquine | 2003 |
The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Drug Therapy, Combination; Malaria; Malaria, Falciparum; Malaria, Vivax; Mefloquine; Mice; Plasmodium berghei; Plasmodium chabaudi; Plasmodium yoelii; Primaquine; Time Factors | 2003 |
The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Malaria; Mice; Plasmodium berghei; Plasmodium yoelii | 1993 |
The chemotherapy of rodent malaria. LIV. Combinations of 'Fenozan B07' (Fenozan-50F), a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane, with other drugs against drug-sensitive and drug-resistant parasites.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Drug Antagonism; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Malaria; Mefloquine; Mice; Naphthyridines; Parasitemia; Phenanthrenes; Phenylpropionates; Plasmodium berghei; Plasmodium yoelii | 1997 |
[New preventive antimalaria drug. 3 tables, 2 months of protection. Interview by Petra Eiden].
Topics: Adolescent; Aminoquinolines; Antimalarials; Humans; Malaria; Randomized Controlled Trials as Topic | 2000 |
Drug use and design in the nineties.
Topics: Aminoquinolines; Amodiaquine; Antimalarials; Artemisinins; Calcium Channel Blockers; Chloroquine; Humans; Malaria; Mefloquine; Naphthoquinones; Phenanthrenes; Primaquine; Quinine; Sesquiterpenes; Sulfadoxine | 1991 |
Sporontocidal activity of the antimalarial WR-238605 against Plasmodium berghei ANKA in Anopheles stephensi.
Topics: Aminoquinolines; Animals; Anopheles; Antimalarials; Female; Insect Vectors; Malaria; Mice; Mice, Inbred ICR; Plasmodium berghei; Salivary Glands | 1990 |